Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52].
Saved in:
| Title: | Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. |
|---|---|
| Authors: | Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: morrism@mskcc.org., Mota JM; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lacuna K; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Hilden P; Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Gleave M; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada., Carducci MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA., Saad F; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada., Cohn ED; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Filipenko J; Prostate Cancer Clinical Trials Consortium, New York, NY, USA., Heller G; Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shore N; Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA., Armstrong AJ; Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery at the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC, USA., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. |
| Source: | European urology oncology [Eur Urol Oncol] 2022 Oct; Vol. 5 (5), pp. 603. Date of Electronic Publication: 2022 Aug 18. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101724904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2588-9311 (Electronic) Linking ISSN: 25889311 NLM ISO Abbreviation: Eur Urol Oncol Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 35985981 AccessLevel: 2 PubTypeId: unknown PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Morris+MJ%22">Morris MJ</searchLink>; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: morrism@mskcc.org.<br /><searchLink fieldCode="AU" term="%22Mota+JM%22">Mota JM</searchLink>; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lacuna+K%22">Lacuna K</searchLink>; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Hilden+P%22">Hilden P</searchLink>; Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Gleave+M%22">Gleave M</searchLink>; Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Carducci+MA%22">Carducci MA</searchLink>; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Saad+F%22">Saad F</searchLink>; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Cohn+ED%22">Cohn ED</searchLink>; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Filipenko+J%22">Filipenko J</searchLink>; Prostate Cancer Clinical Trials Consortium, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Heller+G%22">Heller G</searchLink>; Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Shore+N%22">Shore N</searchLink>; Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA.<br /><searchLink fieldCode="AU" term="%22Armstrong+AJ%22">Armstrong AJ</searchLink>; Divisions of Medical Oncology and Urology, Departments of Medicine and Surgery at the Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Scher+HI%22">Scher HI</searchLink>; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101724904%22">European urology oncology</searchLink> [Eur Urol Oncol] 2022 Oct; Vol. 5 (5), pp. 603. <i>Date of Electronic Publication: </i>2022 Aug 18. – Name: TypePub Label: Publication Type Group: TypPub Data: Published Erratum – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101724904 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2588-9311 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225889311%22">25889311 </searchLink><i>NLM ISO Abbreviation: </i>Eur Urol Oncol <i>Subsets: </i>MEDLINE; PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35985981 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.euo.2022.08.001 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 603 Titles: – TitleFull: Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Morris MJ – PersonEntity: Name: NameFull: Mota JM – PersonEntity: Name: NameFull: Lacuna K – PersonEntity: Name: NameFull: Hilden P – PersonEntity: Name: NameFull: Gleave M – PersonEntity: Name: NameFull: Carducci MA – PersonEntity: Name: NameFull: Saad F – PersonEntity: Name: NameFull: Cohn ED – PersonEntity: Name: NameFull: Filipenko J – PersonEntity: Name: NameFull: Heller G – PersonEntity: Name: NameFull: Shore N – PersonEntity: Name: NameFull: Armstrong AJ – PersonEntity: Name: NameFull: Scher HI IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: 2022 Oct Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 2588-9311 Numbering: – Type: volume Value: 5 – Type: issue Value: 5 Titles: – TitleFull: European urology oncology Type: main |
| ResultId | 1 |
